Erdafitinib HCl (formerly JNJ42756493; JNJ-42756493; Balversa), the hydrochloride salt of Erdafitinib, is an orally bioavailable and pan fibroblast growth factor receptor (FGFR) inhibitor approved as an antineoplastic drug. Erdafitinib acts on FGFR1/2/3/4 with mean pIC50 of ~ 9/8.5/8.5/8.25, respectively. In vitro, the proliferation of cells treated with JNJ-42756493 is decreased, associated with increased apoptotic death and decreased cell survival. In vivo, growth of NCI-H716 tumors is delayed by 5 days by drug treatment alone, although when drug delivery is stopped the relative tumor volume increased compared to control. FGFR is upregulated in many tumor cell types and is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.

纯度：≥98%

CAS：1346242-81-6 (free base)